{"id":"https://openalex.org/W2115477111","doi":"https://doi.org/10.1136/jech.2010.120477.23","title":"P23 Patterns of antiretroviral therapy in a European study of HIV-infected children and adolescents","display_name":"P23 Patterns of antiretroviral therapy in a European study of HIV-infected children and adolescents","publication_year":2010,"publication_date":"2010-09-01","ids":{"openalex":"https://openalex.org/W2115477111","doi":"https://doi.org/10.1136/jech.2010.120477.23","mag":"2115477111"},"language":"en","primary_location":{"id":"doi:10.1136/jech.2010.120477.23","doi":"https://doi.org/10.1136/jech.2010.120477.23","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jech.2010.120477.23","pdf_url":"https://jech.bmj.com/content/jech/64/Suppl_1/A42.2.full.pdf","source":{"id":"https://openalex.org/S156988948","display_name":"Journal of Epidemiology & Community Health","issn_l":"0141-7681","issn":["0141-7681","0142-467X","0143-005X","1470-2738"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Epidemiology and Community Health","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://jech.bmj.com/content/jech/64/Suppl_1/A42.2.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037418686","display_name":"N. M. Alam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"N M Alam","raw_affiliation_strings":["UCL Institute of Child Health, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCL Institute of Child Health, London, UK","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090704136","display_name":"Mario Cortina\u2010Borja","orcid":"https://orcid.org/0000-0003-0627-2624","observed_orcids":["https://orcid.org/0000-0003-0627-2624"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M Cortina-Borja","raw_affiliation_strings":["UCL Institute of Child Health, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCL Institute of Child Health, London, UK","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050410339","display_name":"Claire Thorne","orcid":"https://orcid.org/0000-0003-0389-1956","observed_orcids":["https://orcid.org/0000-0003-0389-1956"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C Thorne","raw_affiliation_strings":["UCL Institute of Child Health, London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCL Institute of Child Health, London, UK","institution_ids":["https://openalex.org/I45129253"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I45129253"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"64","issue":"Suppl 1","first_page":"A42.2","last_page":"A43"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8490999937057495,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.8490999937057495,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.1437000036239624,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.9070000052452087},{"id":"https://openalex.org/keywords/hiv-infected-children","display_name":"HIV-infected children","score":0.6880000233650208},{"id":"https://openalex.org/keywords/hiv-infected-adolescents","display_name":"HIV-infected adolescents","score":0.9369999766349792},{"id":"https://openalex.org/keywords/drug-use-patterns","display_name":"drug use patterns","score":0.5609999895095825},{"id":"https://openalex.org/keywords/zidovudine","display_name":"zidovudine","score":0.781000018119812},{"id":"https://openalex.org/keywords/lamivudine","display_name":"lamivudine","score":0.9929999709129333},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.8569999933242798},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9779999852180481},{"id":"https://openalex.org/keywords/nucleoside-reverse-transcriptase-inhibitors","display_name":"nucleoside reverse transcriptase inhibitors","score":0.8600000143051147},{"id":"https://openalex.org/keywords/polypharmacy","display_name":"polypharmacy","score":0.6340000033378601},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.5270000100135803},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.4180000126361847},{"id":"https://openalex.org/keywords/antiretroviral-drug-resistance","display_name":"antiretroviral resistance","score":0.5400000214576721},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.5680000185966492}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9213697910308838},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.678106963634491},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.6350398659706116},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.6085526943206787},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.501356840133667},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.496345579624176},{"id":"https://openalex.org/C2909970146","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Nucleoside Reverse Transcriptase Inhibitor","level":5,"score":0.48650306463241577},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.4617481529712677},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3715193271636963},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.35883277654647827},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.16426518559455872},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.13121667504310608},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jech.2010.120477.23","doi":"https://doi.org/10.1136/jech.2010.120477.23","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jech.2010.120477.23","pdf_url":"https://jech.bmj.com/content/jech/64/Suppl_1/A42.2.full.pdf","source":{"id":"https://openalex.org/S156988948","display_name":"Journal of Epidemiology & Community Health","issn_l":"0141-7681","issn":["0141-7681","0142-467X","0143-005X","1470-2738"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Epidemiology and Community Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1136/jech.2010.120477.23","doi":"https://doi.org/10.1136/jech.2010.120477.23","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jech.2010.120477.23","pdf_url":"https://jech.bmj.com/content/jech/64/Suppl_1/A42.2.full.pdf","source":{"id":"https://openalex.org/S156988948","display_name":"Journal of Epidemiology & Community Health","issn_l":"0141-7681","issn":["0141-7681","0142-467X","0143-005X","1470-2738"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Epidemiology and Community Health","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8500000238418579,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2115477111.pdf","grobid_xml":"https://content.openalex.org/works/W2115477111.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2123482700","https://openalex.org/W3194672052","https://openalex.org/W2069820433","https://openalex.org/W4240127756","https://openalex.org/W2398913977","https://openalex.org/W2021037491","https://openalex.org/W2025422728","https://openalex.org/W2007047238","https://openalex.org/W4299533610","https://openalex.org/W347553799"],"abstract_inverted_index":{"Background":[0],"Antiretroviral":[1],"therapy":[2],"(ART)":[3],"has":[4],"resulted":[5],"in":[6,11,53,71,187,297,313,325],"increasing":[7],"median":[8,117,244],"survival":[9],"times":[10],"HIV-infected":[12,62],"individuals":[13],"by":[14],"sustaining":[15],"viral":[16,172,283],"load":[17,173],"suppression.":[18],"Since":[19],"children":[20,54],"and":[21,55,74,81,101,105,129,143,190,196,204,208,285,369,393],"adolescents":[22],"are":[23],"likely":[24],"to":[25,29,34,40,202,225],"have":[26],"long-term":[27,330],"exposure":[28,347,368],"ART,":[30,344],"it":[31],"is":[32,384],"important":[33],"understand":[35],"patterns":[36,50],"of":[37,44,51,61,78,85,126,212,238,246,249,257,267,281,318,332,338,357,386,389],"drug":[38,87,240,258],"use":[39,241,259,317,388],"investigate":[41,49],"the":[42,116,177,188,308],"emergence":[43],"unintended":[45],"sequelae.":[46],"Aim":[47],"To":[48],"ART":[52,86,247,292],"adolescents.":[56],"Study":[57],"Design":[58],"Cross-sectional":[59],"analysis":[60],"subjects":[63,153,221,270,339],"aged":[64],"2\u201322":[65],"years":[66,121,251,262],"across":[67],"15":[68,161,169],"clinical":[69],"sites":[70],"Belgium,":[72],"Italy":[73],"Poland.":[75],"Method":[76],"Prevalence":[77],"both":[79],"\u201cever-use\u201d":[80],"\u201ccurrent-use\u201d":[82],"(at":[83],"recruitment)":[84],"classes:":[88],"nucleoside":[89],"analogue":[90,96],"reverse":[91,97],"transcriptase":[92,98],"inhibitors":[93,99,103],"(NRTIs);":[94],"non-nucleoside":[95],"(NNRTIs);":[100],"protease":[102],"(PIs),":[104],"individual":[106,364],"drugs":[107,213,227,365],"were":[108,136,154],"investigated.":[109],"Results":[110],"Among":[111],"468":[112],"participants":[113,358],"(51%":[114],"female)":[115],"age":[118,245],"was":[119,214,234,260,299,320,380],"13.5":[120],"(IQR":[122],"9.9\u201317.0)":[123],"with":[124,168,236,243,290,323,343,345,362,397],"320(68%)":[125],"white":[127],"ethnicity":[128],"104":[130],"(22%)":[131],"Black":[132],"African.":[133],"Overall,":[134],"291(62%)":[135],"virologically":[137],"suppressed":[138],"(HIV-RNA":[139],"\u226450copies/ml)":[140],"at":[141,174,349,378],"enrolment":[142],"35(7%)":[144],"had":[145,162,182,199,222,272,288,340,359],"severe":[146,166],"immuno-suppression":[147],"(age-stratified":[148],"CD4%).":[149],"Only":[150],"23":[151],"(5%)":[152],"ART-naive":[155],"(median":[156,228],"age=10.0":[157],"years,":[158,230],"IQR;":[159,231],"6.1\u201314.3);":[160],"experienced":[163],"moderate":[164],"or":[165,185],"immuno-suppression/HIV-disease,":[167],"having":[170],"detectable":[171],"recruitment.":[175],"Of":[176],"ever-treated":[178],"subjects,":[179],"98%":[180],"(n=436)":[181],"received":[183],"zidovudine":[184],"lamivudine":[186],"past":[189],"72%":[191,197],"(n=324)":[192],"currently;":[193],"82%":[194],"(n=368)":[195],"(n=323)":[198],"been":[200,223,341,360],"ever-exposed":[201],"PIs":[203,319],"NNRTIs,":[205],"respectively.":[206],"Median":[207,254],"modal":[209],"lifetime":[210],"number":[211],"six.":[215],"Over":[216],"their":[217],"lifetime,":[218],"119":[219],"(27%)":[220],"exposed":[224],"\u22658":[226],"age=15.7":[229],"12.3\u201318.0).":[232],"Age":[233],"associated":[235,321,396],"duration":[237,256],"total":[239,255],"(p<0.001),":[242],"initiation":[248],"3.6":[250],"(IQR:":[252],"1.1\u20137.4)":[253],"8.7":[261],"(IQR=5.7\u201311.2":[263],"years).":[264],"Nine":[265],"percent":[266],"currently":[268],"treated":[269,361],"(n=38)":[271],"suboptimal":[273,390],"management,":[274],"defined":[275],"as":[276,307],"NRTIs-only":[277],"(24":[278],"showing":[279],"evidence":[280,385],"incomplete":[282],"suppression),":[284],"91%":[286],"(n=384)":[287],"treatment":[289,376],"combination":[291,310],"(cART).The":[293],"most":[294,374],"common":[295],"PI":[296,311,398],"current-use":[298],"kaletra":[300],"(n=170,":[301],"40%),":[302],"possibly":[303],"reflecting":[304],"its":[305],"availability":[306],"only":[309],"accessible":[312],"tablet/liquid":[314],"form.":[315],"Current":[316],"(p<0.001)":[322],"hypercholesterolaemia":[324,394],"adjusted":[326],"analyses":[327],"indicating":[328],"a":[329,355],"consequence":[331],"specific":[333],"ART.":[334],"Conclusions":[335],"The":[336,373],"majority":[337],"managed":[342],"first":[346],"occurring":[348],"an":[350],"early":[351],"age.":[352],"At":[353],"least":[354],"quarter":[356],"multiple":[363],"suggesting":[366],"cumulative":[367],"switching":[370],"between":[371],"regimens.":[372],"prevalent":[375],"approach":[377],"recruitment":[379],"cART.":[381],"However,":[382],"there":[383],"continued":[387],"management":[391],"strategies,":[392],"being":[395],"use.":[399]},"counts_by_year":[],"updated_date":"2026-09-08T07:41:39.490200","created_date":"2025-10-10T00:00:00"}